APA (7th ed.) Citation

Berger, A. K., Abel, U., Kloor, M., Ose, J., Weber, T., Stange, A., . . . Jäger, D. (2012). A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: The Heidelberg REMOTUX trial. BMC cancer, 12, . https://doi.org/10.1186/1471-2407-12-108

Chicago Style (17th ed.) Citation

Berger, Anne Katrin, Ulrich Abel, Matthias Kloor, Jennifer Ose, Tim Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, and Dirk Jäger. "A Phase II Study for Metabolic in Vivo Response Monitoring with Sequential 18FDG-PET-CT During Treatment with the EGFR-monoclonal-antibody Cetuximab in Metastatic Colorectal Cancer: The Heidelberg REMOTUX Trial." BMC Cancer 12 (2012). https://doi.org/10.1186/1471-2407-12-108.

MLA (9th ed.) Citation

Berger, Anne Katrin, et al. "A Phase II Study for Metabolic in Vivo Response Monitoring with Sequential 18FDG-PET-CT During Treatment with the EGFR-monoclonal-antibody Cetuximab in Metastatic Colorectal Cancer: The Heidelberg REMOTUX Trial." BMC Cancer, vol. 12, 2012, https://doi.org/10.1186/1471-2407-12-108.